Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 5,315 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Myelodysplastic Syndromes
Interventions: Elritercept, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 25
States / cities: Duarte, California • Glendale, California • La Jolla, California + 21 more

Conditions: Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
Interventions: Abetimus sodium (LJP 394); Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 66
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more

Conditions: Cutaneous Lupus Erythematosus
Interventions: CC-11050, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin degludec, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 156
States / cities: Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more

Conditions: Obstructive Sleep Apnea
Interventions: Budesonide, placebo; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 6 Years to 12 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Renal Cell Carcinoma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 61
States / cities: Muscle Shoals, Alabama • Anchorage, Alaska • Chandler, Arizona + 54 more

Conditions: Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
Interventions: cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention, Lifestyle, Medication; Procedure · Behavioral · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 5,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Yuma, Arizona • Beverly Hills, California + 82 more

Conditions: Peripheral T-cell Lymphoma
Interventions: Duvelisib; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Colorectal Neoplasms, Neoplasm Metastasis
Interventions: Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 87
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more

Conditions: Leukemia
Interventions: Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 103
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more

Conditions: Multiple Sclerosis
Interventions: other disease-modifying therapy, Fingolimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 3,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 208
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more

Conditions: Peripheral Arterial Disease
Interventions: Carnosine; Biological
Lead sponsor: Shahid Baba; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Obesity, Overweight
Interventions: LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 49
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Atopic Dermatitis
Interventions: BTX 1204, Vehicle; Drug
Lead sponsor: Botanix Pharmaceuticals; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Encino, California • Fremont, California + 16 more

Conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions: Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 174
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more

Conditions: Prostate Cancer
Interventions: docetaxel, estramustine phosphate sodium, exisulind; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 78
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more

Conditions: Sarcoma
Interventions: dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2011
U.S. locations: 205
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Periodontal Diseases
Interventions: DFDBA, Regenafil; Other · Device
Lead sponsor: RTI Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Indianapolis, Indiana • Louisville, Kentucky

Conditions: Lung Cancer
Interventions: carboplatin, etoposide, exisulind; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 81
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more

Conditions: Arthropathy of Knee, Arthropathy of Hip
Interventions: Mako Robotic-Arm Assisted Arthroplasty; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 5
States / cities: Jacksonville, Florida • Louisville, Kentucky • New York, New York + 2 more

Conditions: Metastatic Prostate Cancer
Interventions: High dose testosterone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more

Conditions: Asthma
Interventions: Albuterol eMDPI DS, albuterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more

Conditions: Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 54
States / cities: Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more

Search by objective public record fields.

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Carnosine for Peripheral Arterial Disease Patients

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Mako-MORE Registry

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight